|Gimv||Partner – Health & Care||Belgium|
ARE IMMUNOTHERAPIES STILL AN INVESTMENT ELDORADO?
Bram Vanparys joined Gimv in 2018.
Bram has over 10 years of international venture capital experience, most recently at Merck Ventures in Amsterdam.
Bram has a successful track record in Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe and Israel, including arGEN-X (ARGX:EBR), Multiplicom (acquired by Agilent), Cartagenia (acquired by Agilent), Q-Biologicals (acquired by Amatsigroup, now Eurofins), Calypso Biotech and iOmx.
Bram is trained as a PhD in biotechnology (University of Ghent, Belgium) and has an executive MBA from Vlerick Business School (Belgium)